In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.

[1]  S. Steinberg,et al.  Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. , 1995, The Journal of infectious diseases.

[2]  J. Craig,et al.  In vitro anti-HIV and Cytotoxicological Evaluation of the Triple Combination: AZT and ddC with HIV Proteinase Inhibitor Saquinavir (Ro 31-8959) , 1994 .

[3]  J. Grange,et al.  Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  H. Mitsuya,et al.  Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. , 1994, The Journal of biological chemistry.

[5]  C. Baboonian,et al.  Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase , 1994, Journal of virology.

[6]  E. White,et al.  Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs. , 1993, Antiviral research.

[7]  P. Volberding,et al.  Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection , 1993, Annals of Internal Medicine.

[8]  D. Lambert,et al.  Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. , 1993, Antiviral research.

[9]  S. Broder,et al.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.

[10]  S. Gulnik,et al.  In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine , 1993, Antimicrobial Agents and Chemotherapy.

[11]  B. Anderson,et al.  Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Bilello,et al.  Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease , 1993, Antimicrobial Agents and Chemotherapy.

[13]  H. Jacobsen,et al.  Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease , 1992, Journal of virology.

[14]  J. Weinstein,et al.  In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations , 1992, Antimicrobial Agents and Chemotherapy.

[15]  J. Zack,et al.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle , 1992, Journal of virology.

[16]  M P Dempsey,et al.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. , 1991, Science.

[17]  O. Takahashi,et al.  Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. , 1991, Chemical & pharmaceutical bulletin.

[18]  J. Weinstein,et al.  Synergistic Drug Combinations in AIDS Therapy , 1990, Annals of the New York Academy of Sciences.

[19]  J. Weinstein,et al.  COMBO: A New Approach to the Analysis of Drug Combinations in Vitro a , 1990 .

[20]  J. Weinstein,et al.  Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Moss,et al.  An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  I. Kuntz,et al.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[24]  M. Stevenson,et al.  HIV‐1 replication is controlled at the level of T cell activation and proviral integration. , 1990, The EMBO journal.

[25]  Jerome A. Zack,et al.  HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.

[26]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[27]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[28]  D. S. Webb,et al.  Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido- 2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine , 1989, The Journal of experimental medicine.

[29]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[30]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[31]  E. Gelmann,et al.  ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX , 1986, The Lancet.

[32]  D W Barry,et al.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Richards Bw.  Sjogren-Larsson syndrome. , 1970, Lancet.

[34]  S. Steinberg,et al.  A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. , 1994, The Journal of infectious diseases.

[35]  D. Norbeck,et al.  A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. , 1994, AIDS research and human retroviruses.

[36]  E. Coligan.  Current protocols in immunology , 1991 .

[37]  D. Leland,et al.  Virus Isolation and Identification , 1988 .

[38]  A. Balows,et al.  Laboratory Diagnosis of Infectious Diseases Principles and Practice , 1988, Springer New York.